The news is directly related to Pliant Therapeutics. While the 'Outperform' rating is maintained, the lowering of the price target might indicate a slightly less optimistic outlook from RBC Capital. However, the impact on the stock price is uncertain in the short term as it depends on how investors interpret this news.